Impotentie brengt een constant ongemak met zich mee, net als fysieke en psychologische problemen in uw leven cialis kopen terwijl generieke medicijnen al bewezen en geperfectioneerd zijn

Microsoft word - gary-swan-cv.docx

Gary Swan, Ph.D.
Director, Center for Health Sciences
SRI International

Curriculum Vitae
B.S., Psychology, University of Washington, Seattle, Washington M.A., Psychology, State University of New York at Stony Brook, New York Ph.D., Psychology, State University of New York at Stony Brook, New York Academic Positions / Employment
Clinical Instructor, Dept. of Psychiatry, Stanford Medical Center, Stanford, CA Licensed Psychologist, California #PI6636 Sr. Health Psychologist, Department of Behavioral Medicine, SRI International, Menlo Park, Director, Center for Health Sciences, SRI International, Menlo Park, CA Honors and Awards
1974 – 1977 Phi Beta Kappa, magna cum laude, New York State Graduate Council Fellowship
1991, 1993
SRI International Professional Excellence Award Elected to Academy of Behavioral Medicine Research SRI Fellow (SRI International's highest honor for researchers) 1998 – 2006 Editor-in-Chief, Nicotine & Tobacco Research
Selected Peer-Reviewed Manuscripts
Carmelli D, Swan GE, Robinette D, Fabsitz RR. Genetic influence on smoking: A study of male twins. N Engl J Med, 327:829-833, 1992. Swan GE, Ward MM, Jack LM, Javitz HS. Cardiovascular reactivity as a predictor of relapse in male and female smokers. Health Psychology, 12:451-458, 1993. Swan GE, Carmelli D, Robinette D. Characteristics associated with excessive weight gain following smoking cessation in adult males. Am J Public Health, 85:73-77, 1995. Swan GE, Ward MM, Carmelli D, Jack LM. The identification of subgroups with differential rates of relapse after cessation of smoking: Implications for alcohol treatment research. In: Fertig J and Allen JP (Eds.) NIAAA Alcohol Research Monograph, Alcohol and Tobacco: From Basic Science to Clinical Practice, U.S. Govt. Printing Office: NIH No. 95-3931:239-263, 1995. Swan GE, Carmelli D, Cardon LR. The consumption of tobacco, alcohol, and coffee in Caucasian male twins: A multivariate genetic analysis. J Substance Abuse, 8:19-31, 1996. Swan GE, Ward MM, Jack LM. Abstinence effects as predictors of 28-day relapse in smokers. Addictive Behav, 21:481-490, 1996. Swan GE, Carmelli D. The genetics of smoking and related issues. In Noble, E.P., and Blum, K. (Eds). Handbook of Psychoneurogenetics, CRC Press, pp. 379-398, 1997. Swan GE, Carmelli D, Cardon LR. Heavy consumption of cigarettes, alcohol, and coffee in male twins. J Studies in Alcohol, 58:182-190, 1997. Swan GE, Jack LM, Ward MM. Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction, 92:207-218, 1997. Cheng LS-C, Swan GE, Carmelli DA. A genetic analysis of smoking behavior in family members of older adult males. Addiction, 95:427-435, 2000. Hudmon KS, Marks JL, Pomerleau CS, Bolt DM, Brigham JZ, Swan GE. A multidimensional model for characterizing tobacco dependence. Nicotine Tob Res, Oct 2003;5(5):655-664. Jack LM, Swan GE, Thompson E, Curry SJ, McAfee T, Dacey S, Bergman K. Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed care setting. Prev Med, 36(5):585-593, 2003. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction.98(1):23-31, 2003. McCaffery JM, Niaura R, Swan GE, Carmelli D. Depressive symptoms and smoking in the NHLBI Twins. Nicotine Tob Res, 5:77-83, 2003. Shenassa ED, McCaffery JM, Swan GE, Khroyan TV, Shakib S, Lerman C, Lyons M, Mouttapa M, Niaura RS, Buka SL, Leslie F, Santangel SL. Intergenerational transmission of tobacco use and dependence: A transdisciplinary perspective. Nicotine Tob Res, Dec 2003;5 Suppl 1:S55-69. Swan GE, Hudmon KS, Cheng LS, Jack LM, Hemberger K, Carmelli D, Khroyan TV, Ring HZ, Hops H, Andrews JA, Tildesley E, McBride D, Benowitz N, Webster C, Wilhelmsen K, Feiler H, Koenig B, Caron L, Illes J. Environmental and genetic determinants of tobacco use: A multidisciplinary, longitudinal family-based design. Cancer Epidemiol Biomarkers Prev 12:994-1005, 2003. Swan GE, McAfee T, Jack LM, Curry SJ, Javitz HS, Dacey S, Bergman K. Effectiveness of bupropion SR for smoking cessation in a health care setting: a randomized trial. Arch Int Med 163:2337-2344, 2003. Swan GE, Jack LM, Curry SJ, Chorost M, Javitz HS, McAfee T, Dacey S. Bupropion SR and counseling for smoking cessation in actual practice: Predictors of outcome. Nicotine Tob Res 5(6): 911-921, 2003. Berrettini, W., Bierut, L., Crowley, T. J., Cubells, J. F., Frascella, J., Gelernter, J., Hewitt, J. K., Kreek, M. J., Lachman, H., Leppert, M., Li, M. D., Lachman, H., Leppert, M., Li, M. D., Madden, P., Miner, C., Pollock, J. D., Pomerleau, O., Rice, J. P., Rutter, J. L., Shurtleff, D., Swan, G. E., Tischfield, J. A., Tsuang, M., Uhl, G. R., Vanyukov, M., Volkow, N. D., Wanke, K., Setting priorities for genomic research. Science, 2004, 304(5676), 1445-1447. Javitz, H., Swan, G. E., Zbikowski, S., Curry, S., McAfee, T., Decker, T., Patterson, G., Jack, L. M. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: A societal perspective. American Journal of Managed Care, 2004, 10(3), 217-226. Lessov CN, Swan GE, Ring HZ, Khroyan TV, Lerman C. Genetics and prevention of drug abuse: Implications for Transdisciplinary research and practice. Substance Use and Misuse, 39(10-12):1515-69. 2004. Swan, G. E., Benowitz, N. L., Jacob III, P., Lessov, C. N., Tyndale, R. F., Wilhelmsen, K., Krasnow, R. E., McElroy, M. R., Moore, S. E., Wambach, M. Pharmacogenetics of nicotine metabolism in twins: Methods and procedures. Twin Research, 2004, 7(5), 435-448. Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T. Heterogeneity in 12-month outcome among female and male smokers following pharmacobehavioral treatment for smoking cessation in actual practice. Addiction 99:237-250, 2004. Swan, G. E., Valdes, A. M., Ring, H. Z., Khroyan, T. V., Jack, L. M, Ton, C. C., Curry, S. J., McAfee, T. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J, 2005;5(1):21-9. Zbikowski, S. M., Swan, G. E., McClure, J. B. Cigarette smoking and nicotine dependence. In: Reichert, V. C., Talwar, A., Fein, A. M. (eds). Treating tobacco dependence. Medical Clinics of North America, 2004, 88(6), 1453-1465. Caron, L., Karkazis, K., Raffin, T. A., Swan, G. E., Koenig, B. A. Nicotine addiction through a neurogenomic prism: Ethics, public health, and smoking. Nicotine & Tobacco Research, 2004 Colrain, I. M., Trinder, J., Swan, G. E. The impact of smoking cessation on objective and subjective markers of sleep: Review, synthesis, and recommendations. Nicotine & Tobacco Research, ;6(6), 913-25. Hudmon, K. S., Pomerleau, C. S., Brigham, J., Javitz, H., Swan, G. E. Validity of retrospective assessments of nicotine dependence: A preliminary report. Addictive Behaviors, Mar 2005;30(3):613-7. Swan, G. E., Benowitz, N. L., Lessov, C. N., Jacob III, P., Tyndale, R. F., Wilhelmsen, K. Nicotine metabolism: The impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics, 2005;15:115-125 Swan, G. E., Valdes, A. M., Ring, H. Z., Khroyan, T. V., Jack, L. M, Ton, C. C., Curry, S. J., McAfee, T. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J, 2005, 5, 21-29. Swan, G. E., Hops, H., Wilhelmsen, K. C., Lessov, C. N., Cheng, L. S.-C., Hudmon, K. S., Amos, C., Feiler, H. S., Ring, H. Z., Andrews, J. A., Tildesley, E., Benowitz, N. L. A genome-wide screen for nicotine dependence susceptibility loci. American Journal of Medical Genetics B Neuropsychiatric Genetics, 2006, 141, 354-360. Bierut, L. J., Madden, P. A. F., Breslau, N., Johnson, E. O., Hatsukami, D., Pomerleau, O. F., Swan, G. E., Rutter, J., Bertelsen, S., et al. Novel genes identified in a high density genome-wide association study for nicotine dependence. Human Molecular Genetics, 2007, 16, 24-35. Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A. F., Breslau, N., Johnson, E. O., Hatsukami, D., Pomerleau, O. F., Swan, G. E., Goate, A. M., Rutter, J., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3,713 SNPs. Human Molecular Genetics, 2007, 16, 36-49. Swan, G. E., Jack, L. M., Valdes, A. M., Ring, H. Z., Ton, C. C., Curry, S. J., McAfee, T. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol, 2007, 26(3), 361-368. Swan, G.E., Lessov-Schlaggar, C.N., Krasnow, R.E., Wilhelmsen, K.C, Jacob, P., 3rd, and Benowitz, N.L., Genetic and environmental sources of variation in heart rate response to infused nicotine in twins. Cancer Epidemiol Biomarkers Prev, 2007; 16: 1057-64. Benowitz, N., Lessov-Schlaggar, C., and Swan, G., Genetic Influences in the Variation in Renal Clearance of Nicotine and Cotinine. Clin Pharmacol Ther, 2008; 84: 243-247. Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Bertelsen, S., Fox, L., Grucza, R. A., Horton, W. J., Kauwe, J. S., Morgan, S. D., Saccone, N. L. Saccone, S. F., Xuei, X., Breslau, N., Budde, J., Cloninger, C. R., Dick, D. M., Foroud, T., Hatsukami, D., Hesselbrock, V., Johnson, E. O., John Kramer, J., Kuperman, S., Madden, P., Mayo, K., Maxwell, T., Nurnberger, Jr., J., Pomerleau, O., Porjesz, B., Reyes, O., Schuckit, M., Swan, G. E., Edenberg, H. J., Rice, J. P., Goate, A. M. An amino acid change in the alpha 5 nicotinic receptor increases risk for nicotine dependence. American Journal of Psychiatry, 2008, 165, 1163-1171, PMCID: PMC2574742. Conti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., Bergen, A. W., Swan, G. E., Tyndale, R. F., Benowitz, N. L., and Lerman, C. for the Pharmacogenetics of Nicotine Addiction and Treatment Consortium. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Human Molecular Genetics, 2008, 17, 2834-2848, PMCID: PMC2525499. Saccone, S. F., Saccone, N. L., Swan, G. E., Madden, P. A. F., Goate, A. M., Rice, J. P., Bierut, L. J. Systematic biological prioritization after a genome-wide association study: An application to nicotine dependence. Bioinformatics, 2008, 24, 1805-1811, PMCID: PMC2610477. He, Y., Bergen, A. W., Hops, H., Andrews, J. A., Tildesley, E., Lessov-Schlaggar, C. N., Webster, C., Benowitz, N., & Swan, G. E. Genome-wide linkage of cotinine pharmacokinetics suggests candidate regions on chromosomes 9 and 11. Am J Med Genet B Neuropsychiatr Genet, 2009; 150B(4), 554-559, PMCID: PMC2693302 [Available on 2010/6/5]. Swan, G. E., Lessov-Schlaggar, C. N., Bergen, A. W., He, Y., Tyndale, R. F., & Benowitz, N. L. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics, 2009; 19(5), 388-398; NIHMSID #175954. Thomas, P. D., Mi, H., Swan, G. E., Lerman, C., Benowitz, N., Tyndale, R. F., Bergen, A. W., & Conti, D. V. A systems biology network model for genetic association studies of nicotine addiction and treatment. Pharmacogenet Genomics, 2009; 19(7), 538-551. Hardin J, He Y, Javitz HS, Wessel J, Krasnow RE, Tildesley E, Hops H, Swan GE, Bergen AW. Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the Smoking in Families (SMOFAM) sample. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3399-406; NIHMSID #155233.



Measuring the quality of life of cancer patients with The Rotterdam Symptom Checklist ()Northern Centre for Healthcare Research (NCH) University of Groningen, The Netherlands Department of Medical Psychology, Academic Medical Center Amsterdam; Department of Medical Decision Making, University Hospital, Leiden, The Netherlands Medical Biometrics, University Hospital Freiburg,

Microsoft word - rx consultant patent expiration table 010711.doc

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities… Estimated Dates of Possible First Time Generic/ Rx-to-OTC Market Entry 2009 US Retail Sales: Brand Name Generic name (in millions)^ Information current as of January 2011. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities

Copyright © 2010-2014 Online pdf catalog